MBX
MBX Biosciences, Inc.
Price Chart
Latest Quote
$59.92
-3.08 (-4.89%)
Current Price
| Previous Close | $63.00 |
| Open | $62.30 |
| Day High | $63.04 |
| Day Low | $59.66 |
| Volume | 248,907 |
Stock Information
| Shares Outstanding | 48.16M |
| Total Debt | $3.34M |
| Cash Equivalents | $418.58M |
| Net Income | $-104.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.97B |
| EPS (TTM) | $-2.37 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.55B |
| Income | $-104.29M |
| Book/sh | $8.54 |
| Cash/sh | $8.69 |
| Employees | 63 |
Financial Ratios
| Quick Ratio | 17.82 |
| Current Ratio | 18.08 |
| Debt/Eq | 0.82 |
Returns & Margins
| ROA | -22.08% |
| ROE | -33.17% |
Ownership
| Insider Ownership | 2.82% |
| Institutional Ownership | 115.75% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -15.57 |
| P/B | 7.21 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $88.36 |
Technical Indicators
| SMA20 | $66.83 |
| SMA50 | $61.88 |
| SMA200 | $39.99 |
| RSI | 37.66 |
| ATR | 2.9445 |
| Shares Float | 30.99M |
| Short Float | 14.35% |
| Short Ratio | 8.26 |
| Rel Volume | 1.19 |
Performance History
| Week | -7.21% |
| Month | -6.57% |
| Quarter | +100.98% |
| 6 Months | +86.84% |
| YTD | +101.64% |
| Year | +331.67% |
| 10 Years | +160.47% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $61.60 | 518,298 |
| 2026-08-28 | $63.00 | 307,600 |
| 2026-08-27 | $66.39 | 263,500 |
| 2026-08-26 | $66.76 | 214,700 |
| 2026-08-25 | $68.62 | 274,000 |
| 2026-08-24 | $66.39 | 531,000 |
| 2026-08-21 | $66.33 | 466,300 |
| 2026-08-20 | $66.35 | 422,500 |
| 2026-08-19 | $68.40 | 562,300 |
| 2026-08-18 | $66.52 | 560,700 |
| 2026-08-17 | $68.25 | 461,200 |
| 2026-08-14 | $68.57 | 503,100 |
| 2026-08-13 | $67.08 | 334,900 |
| 2026-08-12 | $66.97 | 331,400 |
| 2026-08-11 | $66.01 | 359,700 |
| 2026-08-10 | $66.15 | 325,500 |
| 2026-08-07 | $67.82 | 545,500 |
| 2026-08-06 | $67.11 | 528,700 |
| 2026-08-05 | $67.48 | 487,500 |
| 2026-08-04 | $70.70 | 696,000 |
| 2026-08-03 | $64.41 | 390,600 |
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
đ° Latest News
UMH Properties and 4 More Stocks See Action From Activist Investors
Barrons.com âĸ 2026-08-14T23:05:00Z
Stock Market Checklist Helps Uncover Winners In Hot Biotechs
Investor's Business Daily âĸ 2026-07-31T15:09:28Z
How Do MBX Biosciencesâ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?
Simply Wall St. âĸ 2026-06-15T20:14:25Z
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)
InvestorsHub âĸ 2026-06-12T12:52:53Z
J&J looks to widen Imaavyâs use; $300M backs rare disease drug launch
BioPharma Dive âĸ 2026-06-11T09:27:31Z
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
Motley Fool âĸ 2026-05-27T19:38:24Z
Insider Stock Buying Reaches US$1.06m On MBX Biosciences
Simply Wall St. âĸ 2026-05-15T13:18:49Z
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MarketBeat âĸ 2026-05-11T19:09:16Z
3 Overlooked Stocks Set to Soar in 2026
Motley Fool âĸ 2026-05-05T13:05:00Z
Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase
Motley Fool âĸ 2026-04-22T15:00:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $98,055,000 | $68,194,000 | $35,311,000 | $25,161,000 |
| Net Non Operating Interest Income Expense | $11,084,000 | $6,272,000 | $2,748,000 | $-2,000 |
| Operating Expense | $98,055,000 | $68,194,000 | $35,311,000 | $25,161,000 |
| General And Administrative Expense | $18,896,000 | $10,779,000 | $6,777,000 | $3,764,000 |
| Interest Expense | - | - | $0 | $374,000 |
| Interest Expense Non Operating | - | - | $0 | $374,000 |
| Other Income Expense | - | - | - | $-972,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Net Interest Income | $11,084,000 | $6,272,000 | $2,748,000 | $-2,000 |
| Interest Income | $11,084,000 | $6,272,000 | $2,748,000 | $372,000 |
| Normalized Income | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-25,163,000 |
| Net Income From Continuing And Discontinued Operation | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Total Operating Income As Reported | $-98,055,000 | $-68,194,000 | $-35,311,000 | $-25,161,000 |
| Net Income Common Stockholders | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Net Income | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Net Income Including Noncontrolling Interests | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Net Income Continuous Operations | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Pretax Income | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Interest Income Non Operating | $11,084,000 | $6,272,000 | $2,748,000 | $372,000 |
| Operating Income | $-98,055,000 | $-68,194,000 | $-35,311,000 | $-25,161,000 |
| Special Income Charges | - | - | $0 | $-899,000 |
| Per Share | ||||
| Diluted EPS | $-2.38 | $-5.82 | $-1.02 | $-0.82 |
| Basic EPS | $-2.38 | $-5.82 | $-1.02 | $-0.82 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-97,807,000 | $-67,950,000 | $-35,154,000 | $-24,733,000 |
| Reconciled Depreciation | $248,000 | $244,000 | $157,000 | $56,000 |
| EBITDA (Bullshit earnings) | $-97,807,000 | $-67,950,000 | $-35,154,000 | $-25,705,000 |
| EBIT | $-98,055,000 | $-68,194,000 | $-35,311,000 | $-25,761,000 |
| Diluted Average Shares | $36,506,092 | $10,642,954 | $31,853,698 | $31,853,698 |
| Basic Average Shares | $36,506,092 | $10,642,954 | $31,853,698 | $31,853,698 |
| Diluted NI Availto Com Stockholders | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Research And Development | $79,159,000 | $57,415,000 | $28,534,000 | $21,397,000 |
| Selling General And Administration | $18,896,000 | $10,779,000 | $6,777,000 | $3,764,000 |
| Other Gand A | $18,896,000 | $10,779,000 | $6,777,000 | $3,764,000 |
| Total Unusual Items | - | - | $0 | $-972,000 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $-972,000 |
| Other Special Charges | - | - | - | $899,000 |
| Gain On Sale Of Security | - | - | - | $-73,000 |
Fetched: 2026-08-29
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $369,223,000 | $257,442,000 | $-72,468,000 | $-42,605,000 |
| Total Assets | $385,144,000 | $268,535,000 | $84,180,000 | $45,095,000 |
| Total Non Current Assets | $3,605,000 | $1,249,000 | $715,000 | $884,000 |
| Non Current Prepaid Assets | $42,000 | $50,000 | $50,000 | - |
| Non Current Deferred Assets | $341,000 | $0 | - | - |
| Current Assets | $381,539,000 | $267,286,000 | $83,465,000 | $44,211,000 |
| Other Current Assets | $861,000 | $803,000 | $133,000 | $84,000 |
| Prepaid Assets | $4,853,000 | $3,652,000 | $2,448,000 | $1,524,000 |
| Receivables | $2,120,000 | $682,000 | $208,000 | $142,000 |
| Accrued Interest Receivable | $2,120,000 | $682,000 | $208,000 | $142,000 |
| Cash Cash Equivalents And Short Term Investments | $373,705,000 | $262,149,000 | $80,676,000 | $42,461,000 |
| Cash And Cash Equivalents | $75,289,000 | $49,351,000 | $30,523,000 | $24,210,000 |
| Other Non Current Assets | - | - | $50,000 | $42,000 |
| Debt | ||||
| Total Debt | $596,000 | $171,000 | $324,000 | $461,000 |
| Long Term Debt And Capital Lease Obligation | $424,000 | $0 | $171,000 | $324,000 |
| Current Debt And Capital Lease Obligation | $172,000 | $171,000 | $153,000 | $137,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,921,000 | $11,093,000 | $156,648,000 | $87,700,000 |
| Total Non Current Liabilities Net Minority Interest | $426,000 | $42,000 | $152,722,000 | $84,269,000 |
| Other Non Current Liabilities | $2,000 | $42,000 | $194,000 | $66,000 |
| Current Liabilities | $15,495,000 | $11,051,000 | $3,926,000 | $3,431,000 |
| Payables And Accrued Expenses | $11,002,000 | $8,556,000 | $2,408,000 | $2,161,000 |
| Payables | $2,977,000 | $5,335,000 | $1,391,000 | $976,000 |
| Accounts Payable | $2,977,000 | $5,335,000 | $1,391,000 | $976,000 |
| Equity | ||||
| Common Stock Equity | $369,223,000 | $257,442,000 | $-72,468,000 | $-42,605,000 |
| Total Equity Gross Minority Interest | $369,223,000 | $257,442,000 | $-72,468,000 | $-42,605,000 |
| Stockholders Equity | $369,223,000 | $257,442,000 | $-72,468,000 | $-42,605,000 |
| Gains Losses Not Affecting Retained Earnings | $286,000 | $55,000 | $60,000 | $3,000 |
| Other Equity Adjustments | $286,000 | $55,000 | $60,000 | $3,000 |
| Retained Earnings | $-224,476,000 | $-137,505,000 | $-75,583,000 | $-43,020,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $152,357,000 | $83,879,000 |
| Other | ||||
| Ordinary Shares Number | $44,927,953 | $33,421,525 | $31,853,698 | $31,853,698 |
| Share Issued | $44,927,953 | $33,421,525 | $31,853,698 | $31,853,698 |
| Tangible Book Value | $369,223,000 | $257,442,000 | $-72,468,000 | $-42,605,000 |
| Invested Capital | $369,223,000 | $257,442,000 | $-72,468,000 | $-42,605,000 |
| Working Capital | $366,044,000 | $256,235,000 | $79,539,000 | $40,780,000 |
| Capital Lease Obligations | $596,000 | $171,000 | $324,000 | $461,000 |
| Total Capitalization | $369,223,000 | $257,442,000 | $-72,468,000 | $-42,605,000 |
| Additional Paid In Capital | $593,407,000 | $394,887,000 | $3,054,000 | $411,000 |
| Capital Stock | $6,000 | $5,000 | $1,000 | $1,000 |
| Common Stock | $6,000 | $5,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $424,000 | $0 | $171,000 | $324,000 |
| Current Capital Lease Obligation | $172,000 | $171,000 | $153,000 | $137,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,321,000 | $2,324,000 | $1,365,000 | $1,133,000 |
| Current Accrued Expenses | $8,025,000 | $3,221,000 | $1,017,000 | $1,185,000 |
| Net PPE | $3,222,000 | $1,199,000 | $665,000 | $842,000 |
| Accumulated Depreciation | $-670,000 | $-422,000 | $-178,000 | $-56,000 |
| Gross PPE | $3,892,000 | $1,621,000 | $843,000 | $898,000 |
| Leases | $520,000 | $391,000 | $372,000 | $350,000 |
| Construction In Progress | $1,616,000 | $0 | $3,000 | $0 |
| Other Properties | $1,372,000 | $935,000 | $247,000 | $342,000 |
| Machinery Furniture Equipment | $384,000 | $295,000 | $221,000 | $206,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $298,416,000 | $212,798,000 | $50,153,000 | $18,251,000 |
Fetched: 2026-08-29
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-81,878,000 | $-55,555,000 | $-32,107,000 | $-23,563,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-79,949,000 | $-54,681,000 | $-31,978,000 | $-23,122,000 |
| Cash Flow From Continuing Operating Activities | $-79,949,000 | $-54,681,000 | $-31,978,000 | $-23,122,000 |
| Operating Gains Losses | - | - | $69,000 | $972,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,929,000 | $-874,000 | $-129,000 | $-441,000 |
| Investing Cash Flow | $-83,705,000 | $-160,595,000 | $-30,927,000 | $-11,411,000 |
| Cash Flow From Continuing Investing Activities | $-83,705,000 | $-160,595,000 | $-30,927,000 | $-11,411,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $187,948,000 | $238,042,000 | $68,509,000 | $36,491,000 |
| Financing Cash Flow | $189,592,000 | $234,104,000 | $69,218,000 | $46,063,000 |
| Cash Flow From Continuing Financing Activities | $189,592,000 | $234,104,000 | $69,218,000 | $46,063,000 |
| Net Other Financing Charges | $-771,000 | $-4,341,000 | $-30,000 | $-458,000 |
| Net Preferred Stock Issuance | $0 | $63,500,000 | $68,509,000 | $36,491,000 |
| Preferred Stock Issuance | $0 | $63,500,000 | $68,509,000 | $36,491,000 |
| Net Common Stock Issuance | $187,948,000 | $174,542,000 | $0 | - |
| Common Stock Issuance | $187,948,000 | $174,542,000 | $0 | - |
| Other | ||||
| End Cash Position | $75,289,000 | $49,351,000 | $30,523,000 | $24,210,000 |
| Beginning Cash Position | $49,351,000 | $30,523,000 | $24,210,000 | $12,680,000 |
| Changes In Cash | $25,938,000 | $18,828,000 | $6,313,000 | $11,530,000 |
| Proceeds From Stock Option Exercised | $2,415,000 | $403,000 | $739,000 | $30,000 |
| Net Investment Purchase And Sale | $-81,776,000 | $-159,721,000 | $-30,798,000 | $-10,970,000 |
| Sale Of Investment | $276,372,000 | $79,750,000 | $33,000,000 | $9,250,000 |
| Purchase Of Investment | $-358,148,000 | $-239,471,000 | $-63,798,000 | $-20,220,000 |
| Net PPE Purchase And Sale | $-1,929,000 | $-874,000 | $-129,000 | $-441,000 |
| Purchase Of PPE | $-1,929,000 | $-874,000 | $-129,000 | $-441,000 |
| Change In Working Capital | $1,575,000 | $4,597,000 | $-735,000 | $1,290,000 |
| Change In Other Current Liabilities | $425,000 | $-153,000 | $-137,000 | $0 |
| Change In Other Current Assets | $-493,000 | $0 | $-8,000 | $-42,000 |
| Change In Payables And Accrued Expense | $4,340,000 | $7,098,000 | $457,000 | $2,123,000 |
| Change In Accrued Expense | $6,796,000 | $3,171,000 | $45,000 | $1,452,000 |
| Change In Payable | $-2,456,000 | $3,927,000 | $412,000 | $671,000 |
| Change In Account Payable | $-2,456,000 | $3,927,000 | $412,000 | $671,000 |
| Change In Prepaid Assets | $-2,697,000 | $-2,348,000 | $-1,047,000 | $-791,000 |
| Other Non Cash Items | $133,000 | $106,000 | $95,000 | $416,000 |
| Stock Based Compensation | $8,677,000 | $5,222,000 | $2,043,000 | $306,000 |
| Amortization Of Securities | $-3,611,000 | $-2,928,000 | $-1,044,000 | $-27,000 |
| Depreciation Amortization Depletion | $248,000 | $244,000 | $157,000 | $56,000 |
| Depreciation And Amortization | $248,000 | $244,000 | $157,000 | $56,000 |
| Depreciation | $248,000 | $244,000 | $157,000 | $56,000 |
| Net Income From Continuing Operations | $-86,971,000 | $-61,922,000 | $-32,563,000 | $-26,135,000 |
| Gain Loss On Sale Of PPE | - | $0 | $69,000 | $0 |
| Issuance Of Debt | - | - | $0 | $10,000,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $10,000,000 |
| Net Long Term Debt Issuance | - | - | $0 | $10,000,000 |
| Long Term Debt Issuance | - | - | $0 | $10,000,000 |
| Gain Loss On Investment Securities | - | - | - | $73,000 |
Fetched: 2026-08-29